Capital Impact Advisors buys $3,767,593 stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Capital Impact Advisors scooped up 23,966 additional shares in United Therapeutics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 30,095 shares of United Therapeutics Corporation which is valued at $3,767,593.United Therapeutics Corporation makes up approximately 1.67% of Capital Impact Advisors’s portfolio.

Other Hedge Funds, Including , Babson Capital Management boosted its stake in UTHR in the latest quarter, The investment management firm added 3,300 additional shares and now holds a total of 17,070 shares of United Therapeutics Corporation which is valued at $2,136,993. United Therapeutics Corporation makes up approx 0.11% of Babson Capital Management’s portfolio.Thrivent Financial For Lutherans boosted its stake in UTHR in the latest quarter, The investment management firm added 560 additional shares and now holds a total of 6,270 shares of United Therapeutics Corporation which is valued at $784,941.Oxbow Advisors reduced its stake in UTHR by selling 17,425 shares or 49.23% in the most recent quarter. The Hedge Fund company now holds 17,970 shares of UTHR which is valued at $2,243,734. United Therapeutics Corporation makes up approx 0.31% of Oxbow Advisors’s portfolio.Smith Asset Management Group Lp reduced its stake in UTHR by selling 1,034 shares or 0.37% in the most recent quarter. The Hedge Fund company now holds 279,156 shares of UTHR which is valued at $31,600,459. United Therapeutics Corporation makes up approx 0.92% of Smith Asset Management Group Lp’s portfolio.

United Therapeutics Corporation opened for trading at $122.75 and hit $123.47 on the upside on Thursday, eventually ending the session at $123.21, with a gain of 0.76% or 0.93 points. The heightened volatility saw the trading volume jump to 4,20,082 shares. Company has a market cap of $5,356 M.

On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *